Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2020
This phase II trial investigates the how well acalabrutinib and obinutuzumab work in treating patients with chronic lymphocytic leukemia (CLL). Acalabrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab may induce changes in body\'s immune system and may interfere with the ability of tumor cells to grow and spread. Giving acalabrutinib and obinutuzumab may help to control disease progression in CLL patients who have not received treatment for CLL.
Epistemonikos ID: b705448ad22f377bec069a9ecee2099265b4c100
First added on: May 07, 2024